Fig. 4From: The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatmentNomograms for prediction of the outcome of patients with breast cancer. a Nomogram developed by integrating the signature risk-score with the clinicopathologic features in the TCGA-BRCA cohort. And calibration curves of nomogram for predicting overall survival at 1-year, 3-year and 5-year in the TCGA-BRCA cohort. b Validated by METABRIC cohort. c Validated by GSE86166 cohortBack to article page